Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...
This week's stock market saw the S&P 500 rise 3.4%, fueled by positive inflation data and strong earnings reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback